These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 7059413)

  • 21. Pharmacokinetics of cimetidine in advanced cirrhosis.
    Grahnén A; Jameson S; Lööf L; Tyllström J; Lindström B
    Eur J Clin Pharmacol; 1984; 26(3):347-55. PubMed ID: 6734697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cimetidine pharmacokinetics and dosage requirements in children.
    Somogyi A; Becker M; Gugler R
    Eur J Pediatr; 1985 May; 144(1):72-6. PubMed ID: 4018106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cimetidine pharmacokinetics after oral administration of cimetidine retard in normal and impaired renal function.
    Shaheen RA; Zazgornik J; Kuska J; Kokot F; Schneider J
    Int J Clin Pharmacol Ther Toxicol; 1990 Nov; 28(11):480-6. PubMed ID: 2272709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.
    Erikson LO; Wåhlin-Boll E; Odar-Cederlöf I; Lindholm L; Melander A
    Eur J Clin Pharmacol; 1989; 36(2):165-74. PubMed ID: 2721541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tinidazole pharmacokinetics in severe renal failure.
    Robson RA; Bailey RR; Sharman JR
    Clin Pharmacokinet; 1984; 9(1):88-94. PubMed ID: 6692632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cimetidine clearance during intermittent and chronic peritoneal dialysis.
    Hyneck ML; Murphy JF; Lipschutz DE
    Am J Hosp Pharm; 1981 Nov; 38(11):1760-2. PubMed ID: 7304634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients].
    Fillastre JP; Humbert G; Leroy A; Godin M
    Presse Med; 1984 Mar; 13(13):797-801. PubMed ID: 6231597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elimination of guanfacine in patients with normal and impaired renal function.
    Kirch W; Köhler H; Braun W
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):33S-35S. PubMed ID: 6994776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
    Merdjan H; Baumelou A; Diquet B; Chick O; Singlas E
    Br J Clin Pharmacol; 1985 Feb; 19(2):211-7. PubMed ID: 3986079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin.
    Misiak PM; Eldon MA; Toothaker RD; Sedman AJ
    J Clin Pharmacol; 1993 Jan; 33(1):53-6. PubMed ID: 8429114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy.
    Cello JP; Oie S
    Eur J Clin Pharmacol; 1983; 25(2):223-9. PubMed ID: 6628505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability and pharmacokinetics of cimetidine.
    Grahnén A; von Bahr C; Lindström B; Rosén A
    Eur J Clin Pharmacol; 1979 Nov; 16(5):335-40. PubMed ID: 520401
    [No Abstract]   [Full Text] [Related]  

  • 33. Increased cimetidine clearance in burn patients.
    Martyn JA; Greenblatt DJ; Abernethy DR
    JAMA; 1985 Mar; 253(9):1288-91. PubMed ID: 3968854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil.
    Harvey VJ; Slevin ML; Dilloway MR; Clark PI; Johnston A; Lant AF
    Br J Clin Pharmacol; 1984 Sep; 18(3):421-30. PubMed ID: 6487480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of oral cefatrizine in patients with impaired renal function.
    Couet W; Fauvel JP; Laville M; Pozet N; Fourtillan JB
    Int J Clin Pharmacol Ther Toxicol; 1991 Jun; 29(6):213-7. PubMed ID: 1869342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
    Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
    Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S; Tan K; Layton G; Leclerc V; Weil A
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cimetidine pharmacokinetics].
    Katrukha SP; Karpenko EV; Davydov SM; Blinkov IL; Kukes VG
    Farmakol Toksikol; 1986; 49(5):36-40. PubMed ID: 3770173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.